TY - JOUR
T1 - PTH assays in dialysis patients
T2 - Practical considerations
AU - Soliman, Mohanad
AU - Hassan, Waleed
AU - Yaseen, Maria
AU - Rao, Madhumathi
AU - Sawaya, B. Peter
AU - El-Husseini, Amr
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Parathyroid hormone (PTH) 1-84 is the main biologically active hormone produced by the parathyroid cells. Circulating PTH molecules include the whole PTH 1-84 along with amino (N) and carboxyl (C) terminal fragments. While PTH is the best available noninvasive biomarker to assess bone turnover in dialysis patients, the biological roles of individual circulating PTH fragments are still not completely known. The understanding that there is an enormous variation in the target specificity of currently available PTH assays for different circulating forms of PTH has led to the evolution of assays from first to second then third generation. With a reduction in kidney function, there is a preferential increase in circulating C fragments and non-PTH 1-84 forms, resulting in a decrease in the ratio of PTH 1-84/non-PTH 1-84. However, there are also substantial differences in between-assay measurements, with several fold variations in results. Targets based on multiples of the upper limit of normal (ULN) should be used rather than PTH ranges using absolute iPTH values. To date, the second-generation PTH remains the most widely used assay. Current guidelines recommend following iPTH trends rather than absolute values. Herein, we highlight problems and challenges in PTH assays/measurements and their interpretations in dialysis patients.
AB - Parathyroid hormone (PTH) 1-84 is the main biologically active hormone produced by the parathyroid cells. Circulating PTH molecules include the whole PTH 1-84 along with amino (N) and carboxyl (C) terminal fragments. While PTH is the best available noninvasive biomarker to assess bone turnover in dialysis patients, the biological roles of individual circulating PTH fragments are still not completely known. The understanding that there is an enormous variation in the target specificity of currently available PTH assays for different circulating forms of PTH has led to the evolution of assays from first to second then third generation. With a reduction in kidney function, there is a preferential increase in circulating C fragments and non-PTH 1-84 forms, resulting in a decrease in the ratio of PTH 1-84/non-PTH 1-84. However, there are also substantial differences in between-assay measurements, with several fold variations in results. Targets based on multiples of the upper limit of normal (ULN) should be used rather than PTH ranges using absolute iPTH values. To date, the second-generation PTH remains the most widely used assay. Current guidelines recommend following iPTH trends rather than absolute values. Herein, we highlight problems and challenges in PTH assays/measurements and their interpretations in dialysis patients.
UR - http://www.scopus.com/inward/record.url?scp=85052784720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052784720&partnerID=8YFLogxK
U2 - 10.1111/sdi.12743
DO - 10.1111/sdi.12743
M3 - Editorial
C2 - 30168196
AN - SCOPUS:85052784720
SN - 0894-0959
VL - 32
SP - 9
EP - 14
JO - Seminars in Dialysis
JF - Seminars in Dialysis
IS - 1
ER -